JPRN-jRCT2080220262未知1 期
Phase I/II study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in advanced and/or metastatic colorectal cancer
试验速览
- 阶段
- 1 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •No previously treated for advanced or metastatic disease, PS 0-1
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal CancerColorectal CancerNCT00345761Chugai Pharmaceutical64
已完成
不适用
Phase II study of Capecitabine + oxaliplatin(CapeOx) for elderly patients with untreated metastatic gastric cancer <TCOG GI-1601>ntreated metastatic gastric cancerJPRN-UMIN000022450The Tokyo Cooperative Oncology Group110
已完成
不适用
A Phase II Study of Capecitabine, Oxaliplatin (XELOX) and Bevacizumab for patient with high-risk Upper Rectal Cancer as Neo-Adjuvant chemotherapy.pper rectal cancerJPRN-UMIN000015765Cancer Institute Hospital of Japanese Foundation for Cancer Research19
进行中（未招募）
不适用
Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer - BOXERMetastatic colorectal adenocarcinoma with metastases involving the liver onlyMedDRA version: 8.1Level: PTClassification code 10010035Term: Colorectal cancer stage IVEUCTR2005-004505-29-GBRoyal Marsden NHS Trust46
未知
2 期
A phase 2 study of capecitabine (R340) in patients who have failed previous treatment with taxane for metastatic breast cancer.breast cancerJPRN-jRCT2080220019Chugai Pharmaceutical Co., Ltd.